Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Equity Average (2018 - 2025)

Arcus Biosciences (RCUS) has 8 years of Equity Average data on record, last reported at $533.5 million in Q4 2025.

  • For Q4 2025, Equity Average changed N/A year-over-year to $533.5 million; the TTM value through Dec 2025 reached $533.5 million, changed N/A, while the annual FY2023 figure was $559.5 million, 25.35% down from the prior year.
  • Equity Average reached $533.5 million in Q4 2025 per RCUS's latest filing, up from $492.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $819.5 million in Q1 2022 and bottomed at $491.0 million in Q4 2023.
  • Average Equity Average over 5 years is $615.3 million, with a median of $584.5 million recorded in 2024.
  • Peak YoY movement for Equity Average: soared 283.01% in 2021, then dropped 27.58% in 2023.
  • A 5-year view of Equity Average shows it stood at $692.3 million in 2021, then decreased by 2.07% to $678.0 million in 2022, then fell by 27.58% to $491.0 million in 2023, then rose by 22.2% to $600.0 million in 2024, then fell by 11.08% to $533.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $533.5 million in Q4 2025, $492.5 million in Q3 2025, and $540.0 million in Q2 2025.